General Information of Drug (ID: DMNC1A3)

Drug Name
HOE-065 Drug Info
Synonyms 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid n-octyl ester maleate
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
6444220
CAS Number
CAS 123060-44-6
TTD Drug ID
DMNC1A3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Incobotulinum toxin A DMKE6YT Cervical cancer 2C77.0 Approved [3]
Abobotulinum toxin A DMZT2P0 Cervical cancer 2C77.0 Approved [4]
KW-6055 DM76O23 Inflammation 1A00-CA43.1 Discontinued in Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholine release (Ach rele) TTZJD1B NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006815)
2 Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol. 1989 Nov 14;171(1):79-85.
3 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 Effects of KW-6055, a novel benzylpyridine derivative, on central cholinergic systems. Nihon Yakurigaku Zasshi. 1992 Jun;99(6):435-43.